GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medtronic PLC (NYSE:MDT) » Definitions » Operating Income
中文

Medtronic (Medtronic) Operating Income

: $6,141 Mil (TTM As of Jan. 2024)
View and export this data going back to 1980. Start your Free Trial

Medtronic's Operating Income for the three months ended in Jan. 2024 was $1,503 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2024 was $6,141 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Medtronic's Operating Income for the three months ended in Jan. 2024 was $1,503 Mil. Medtronic's Revenue for the three months ended in Jan. 2024 was $8,089 Mil. Therefore, Medtronic's Operating Margin % for the quarter that ended in Jan. 2024 was 18.58%.

Warning Sign:

Medtronic PLC operating margin has been in a 5-year decline. The average rate of decline per year is -2.7%.

Medtronic's 5-Year average Growth Rate for Operating Margin % was -2.70% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medtronic's annualized ROC % for the quarter that ended in Jan. 2024 was 7.20%. Medtronic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was 57.67%.


Medtronic Operating Income Historical Data

The historical data trend for Medtronic's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medtronic Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,632.00 5,222.00 4,895.00 5,908.00 5,830.00

Medtronic Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,429.00 1,830.00 1,363.00 1,445.00 1,503.00

Medtronic Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,141 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medtronic  (NYSE:MDT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medtronic's annualized ROC % for the quarter that ended in Jan. 2024 is calculated as:

ROC % (Q: Jan. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2023 ) + Invested Capital (Q: Jan. 2024 ))/ count )
=6012 * ( 1 - 9.17% )/( (75792 + 75926)/ 2 )
=5460.6996/75859
=7.20 %

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Medtronic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2023  Q: Jan. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6640/( ( (5735 + max(6027, 0)) + (5838 + max(5428, 0)) )/ 2 )
=6640/( ( 11762 + 11266 )/ 2 )
=6640/11514
=57.67 %

where Working Capital is:

Working Capital(Q: Oct. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5934 + 5754 + 2659) - (6561 + 0 + 1759)
=6027

Working Capital(Q: Jan. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5968 + 5726 + 2498) - (6589 + 0 + 2175)
=5428

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Medtronic's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2024 )/Revenue (Q: Jan. 2024 )
=1503/8089
=18.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Medtronic Operating Income Related Terms

Thank you for viewing the detailed overview of Medtronic's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Medtronic (Medtronic) Business Description

Address
Lower Hatch Street, 20 On Hatch, Dublin, IRL, 2
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Executives
Brett A. Wall officer: EVP & Group Pres Restora Thera 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Gregory L Smith officer: EVP Global Ops & Supply Chain 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Michael Marinaro officer: EVP & President, Surgical OU 710 MEDTRONIC PARKWAY NE, LC300, MINNEAPOLIS MN 55432
Hoedt Rob Ten officer: EVP & President EMEAC 710 MEDTRONIC PKWY, MSLC300, MINNEAPOLIS MN 55432
Gregory P Lewis director C/O HONEYWELL INTERNATIONAL INC., 300 SOUTH TRYON STREET, CHARLOTTE NC 28202
Sean Salmon officer: EVP & Group President Diabetes MEDTRONIC PLC, 710 MEDTRONIC PARKWAY, LC300, MINNEAPOLIS MN 55432
Lidia Fonseca director 358 SOUTH MAIN STREET, BURLINGTON NC 27215
Karen L Parkhill officer: EVP & Chief Financial Officer 1717 MAIN STREET, MC 6402, DALLAS TX 75201
Ivan K Fong officer: EVP GENERAL COUNSEL & SECR 3M CENTER, ST. PAUL MN 55144-1000
Robert John White officer: EVP & President MITG MEDTRONIC PLC, 710 MEDTRONIC PKWY MS LC300, MINNEAPOLIS MN 55432
Richard H Anderson director MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Bradley E Lerman officer: SVP General Counsel & Corp Sec MEDTRONIC, INC., 710 MEDTRONIC PKWY MSLC300, MINNEAPOLIS MN 55432
Geoffrey Martha officer: Sr VP, Strategy & Bus Dev 710 MEDTRONIC PKWAY, MS LC300, MINNEAPOLIS MN 55432
Jennifer M Kirk officer: Chief Accounting Officer 5 GREENWAY PLAZA, SUITE 110, HOUSTON TX 77046
John R Liddicoat officer: EVP & President of Americas MEDTRONIC PLC, 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432

Medtronic (Medtronic) Headlines

From GuruFocus

Q2 2023 Medtronic PLC Earnings Call Transcript

By GuruFocus Research 01-23-2024

Medtronic PLC ESG Investor Meeting Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Medtronic PLC Earnings Call Transcript

By GuruFocus Research 01-23-2024

Medtronic PLC Investor Briefing Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Medtronic PLC Earnings Call Transcript

By GuruFocus Research 01-23-2024